News

TrakCel announces new group Chief Executive Officer

TrakCel, a leading provider of traceability technology to aid in the delivery of regenerative therapies, today announced that it has appointed a new group Chief Executive Officer.

Mr. Ravi Nalliah joins the company from PCI Services Inc. a US-headquartered global leader for drug development services and a trusted partner to the world’s largest and most successful pharmaceutical firms. He replaces Keren Winmill, who has stepped back to focus exclusively on her role as Chairman of the Board.

“Ravi has excellent business acumen, excels at strategy definition and execution and has a thorough knowledge of TrakCel’s business. He is a respected and capable leader with the drive, ability and energy to adapt quickly to market changes in close collaboration with the Board, the executive team and our employees.” Keren Winmill, Chairman

Nalliah was a key member of the team that, in 2009, led the management buy-out (MBO) of Biotec Services International (Biotec), a leading UK based clinical trials services and supply group specialising in clinical trial services for Phase I to IV trials. He was Chief Finance and Strategy officer of the business and its subsidiaries before leading the sale of the business to PCI Services Inc. in 2014.

During his tenure at Biotec, Nalliah identified the need for a digital solution to manage the complexities of the then emergent cell therapy market and led a board-level initiative to establish the TrakCel business unit and provide start-up financing.

“I am excited about the opportunity to lead TrakCel into the next phase of its strategic development. The fast-paced changes of cell therapy demand that we adapt quickly and efficiently. Moving ahead our set-up must continue to effectively respond to these challenges while retaining a laser-sharp focus on our customers’ needs.” Ravi Nalliah, CEO

Mr. Nalliah is a qualified Chartered Accountant and also holds a Bachelor of Science (BSc), Biochemistry and Molecular Biology. The announcement is part of a series of strategic developments within the business as it builds upon its Clinical and commercial success across the globe.

View the TrakCel profile here